Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1451-1462

  Jabbour, Elias J ^a   Hughes, Timothy P ^b   Cortés, Jorge E ^a   Kantarjian, Hagop M ^a   Hochhaus, Andreas ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Drug resistance; Myeloid leukemias and dysplasias; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RNA BINDING PROTEIN;

ADVANCED CANCER; BLAST CELL CRISIS; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER THERAPY; CENTROSOME; CHROMOSOME ABERRATION; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TELOMERE; TELOMERE LENGTH; BLAST CRISIS; CANCER STAGING; DISEASE COURSE; DISEASE MANAGEMENT; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

BLAST CRISIS; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 84903461580     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.845883     Document Type: Review

References (149)

1. Kantarjian H, O ' Brien S, Jabbour E, et al. Improved survival inchronic myeloid leukemia since the introduction of imatinib therapy: asingle-institution historical experience. Blood 2012; 119: 1981-1987.
2. Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targetedtherapy in chronic myeloid leukemia: a population-based studyof patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol2011 ; 29 : 2514-2520.
3. Hehlmann R. How I treat CML blast crisis. Blood 2012 ; 120 :737-747.
4. Kantarjian HM, Keating MJ, Smith TL, et al. Proposal for a simplesynthesis prognostic staging system in chronic myelogenous leukemia.Am J Med 1990 ; 88 : 1-8.
5. Savage DG, Szydlo RM, Chase A, et al. Bone marrow transplantationfor chronic myeloid leukaemia: the eff ects of diff ering criteria fordefi ning chronic phase on probabilities of survival and relapse. Br JHaematol 1997 ; 99 : 30-35.
6. Sokal J E, Baccarani M, Russo D, et al. Staging and prognosis inchronic myelogenous leukemia. Semin Hematol 1988; 25: 49-61.
7. Swerdlow SH, Campo E, Harris NL, et al., editors. World HealthOrganization classifi cation of tumours of haematopoietic and lymphoidtissues. 4Thed. Geneva: WHO Press ; 2008.
8. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts inthe management of chronic myeloid leukemia: recommendationsfrom an expert panel on behalf of the European LeukemiaNet. Blood2006 ; 108 : 1809-1820.
9. Cortes J E, Talpaz M, O ' B rien S, et al. Staging of chronic myeloidleukemia in the imatinib era. Cancer 2006 ; 106 : 1306-1315.
10. Nowell PC, Hungerford DA. Chromosome studies on normal andleukemic human leukocytes. JNatl Cancer Inst 1960 ; 25 : 85-109.
11. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl andbcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554.
12. Perrotti D, Jamieson C, Goldman J, et al. Chronic myeloidleukemia: mechanisms of blastic transformation. J Clin Invest2010 ; 120 : 2254-2264.
13. Gaiger A, Henn T, HorThe, et al. Increase of bcr-abl chimericmRNA expression in tumor cells of patients with chronic myeloidleukemia precedes disease progression. Blood 1995 ; 86 : 2371-2378.
14. Lin F, van Rhee F, Goldman J M, et al. Kinetics of increasing BCRABLtranscript numbers in chronic myeloid leukemia patients whorelapse after bone marrow transplantation. Blood 1996 ; 87 : 4473-4478.
15. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300patients with BCR-ABL-positive leukemias treated with imatinib in asingle center: a 4.5-year follow-up. Cancer 2005; 103: 1659-1669.
16. Koptyra M, Falinski R, Nowicki M O, et al. BCR/ABL kinase inducesself-mutagenesis via reactive oxygen species to encode imatinibresistance. Blood 2006 ; 108 : 319-327.
17. Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosinekinase induces production of reactive oxygen species in hematopoieticcells. JBiol Chem 2000 ; 275 : 24273-24278.
18. Flis K, Irvine D, Copland M, et al. Chronic myeloid leukemia stemcells display alterations in expression of genes involved in oxidativephosphorylation. Leuk Lymphoma 2012; 53: 2474-2478.
19. Nowicki M O, Falinski R, Koptyra M, et al. BCR/ABL oncogenickinase promotes unfaithful repair of the reactive oxygen speciesdependentDNA double-strand breaks. Blood 2004 ; 104 : 3746-3753.
20. Deutsch E, Dugray A, Abdul Karim B, et al. BCR-ABL downregulatesthe DNA repair protein DNA-PKcs. Blood 2001 ; 97 : 2084-2090.
21. Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinasesinduce drug resistance by stimulation of homology-dependentrecombination repair, prolongation of G(2)/M phase, and protectionfrom apoptosis. Mol Cell Biol 2002; 22: 4189-4201.
22. Slupianek A, Poplawski T, Jozwiakowski SK, et al. BCR/ABLstimulates WRN to promote survival and genomic instability. CancerRes 2011; 71: 842-851.
23. Slupianek A, Dasgupta Y, Ren SY, et al. Targeting RAD51phosphotyrosine- 315 to prevent unfaithful recombination repair inBCR-ABL1 leukemia. Blood 2011 ; 118 : 1062-1068.
24. Johansson B, Fioretos T, Mitelman F. Cytogenetic and moleculargenetic evolution of chronic myeloid leukemia. Acta Haematol2002 ; 107 : 76-94.
25. Mitelman F, Levan G, Nilsson P G, et al. Non-random karyotypicevolution in chronic myeloid leukemia. Int J Cancer 1976; 18: 24-30.
26. Jennings BA, Mills KI. c-myc locus amplifi cation and theacquisition of trisomy 8 in the evolution of chronic myeloid leukaemia.Leuk Res 1998; 22: 899-903.
27. Honda H, Ushijima T, Wakazono K, et al. Acquired loss ofp53 induces blastic transformation in p210(bcr/abl)-expressinghematopoietic cells: a transgenic study for blast crisis of human CML.Blood 2000 ; 95 : 1144-1150.
28. Iervolino A, Santilli G, Trotta R, et al. hnRNP A1 nucleocytoplasmicshuttling activity is required for normal myelopoiesis and BCR/ABLleukemogenesis. Mol Cell Biol 2002 ; 22 : 2255-2266.
29. von Lindern M, van Baal S, Wiegant J, et al. Can, aputativeoncogene associated with myeloid leukemogenesis, may be activatedby fusion of its 3 ' half to diff erent genes: characterization of the setgene. Mol Cell Biol 1992 ; 12 : 3346-3355.
30. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressorPP2A is functionally inactivated in blast crisis CML through theinhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell2005 ; 8 : 355-368.
31. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associatedprotein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996 ; 271 : 11059-11062.
32. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activityin blast crisis and imatinib-resistant chronic myelogenous leukaemia.Br J Cancer 2006 ; 95 : 775-781.
33. Eiring AM, Neviani P, Santhanam R, et al. Identifi cation ofnovel posttranscriptional targets of the BCR/ABL oncoprotein byribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood2008 ; 111 : 816-828.
34. Bornens M. The centrosome in cells and organisms. Science2012 ; 335 : 422-426.
35. Chan JY. Aclinical overview of centrosome amplifi cation inhuman cancers. Int J Biol Sci 2011; 7: 1122-1144.
36. Giehl M, Fabarius A, Frank O, et al. Centrosome aberrationsin chronic myeloid leukemia correlate with stage of disease andchromosomal instability. Leukemia 2005; 19: 1192-1197.
37. Patel H, Gordon MY. Abnormal centrosome-centriole cycle inchronic myeloid leukaemia? Br J Haematol 2009 ; 146 : 408-417.
38. Giehl M, Leitner A, Haferlach C, et al. Detection of centrosomeaberrations in disease-unrelated cells from patients with tumor treatedwith tyrosine kinase inhibitors. Eur J Haematol 2010 ; 85 : 139-148.
39. Stein B L. Chronic myeloid leukemia and risk of second malignancyin two eras of treatment. Leuk Lymphoma 2012 ; 53 : 1651-1653.
40. Blackburn EH. Structure and function of telomeres. Nature1991 ; 350 : 569-573.
41. Raynaud CM, Sabatier L, Philipot O, et al. Telomere length, telomeric proteins and genomic instability during the multistepcarcinogenic process. Crit Rev Oncol Hematol 2008; 66: 99-117.
42. Brümmendorf T H, Holyoake T L, Rufer N, et al. Prognosticimplications of diff erences in telomere length between normal andmalignant cells from patients with chronic myeloid leukemia measuredby fl ow cytometry. Blood 2000 ; 95 : 1883-1890.
43. Drummond M, Lennard A, Brummendorf T, et al. Telomereshortening correlates with prognostic score at diagnosis and proceedsrapidly during progression of chronic myeloid leukemia. LeukLymphoma 2004; 45: 1775-1781.
44. Wong KK, Chang S, Weiler SR, et al. Telomere dysfunction impairsDNA repair and enhances sensitivity to ionizing radiation. Nat Genet2000 ; 26 : 85-88.
45. Plentz RR, Schlegelberger B, Flemming P, et al. Telomereshortening correlates with increasing aneuploidy of chromosome 8 inhuman hepatocellular carcinoma. Hepatology 2005 ; 42 : 522-526.
46. Brümmendorf TH, Ersoz I, Hartmann U, et al. Normalization ofpreviously shortened telomere length under treatment with imatinibargues against a preexisting telomere length defi cit in normalhematopoietic stem cells from patients with chronic myeloid leukemia.Ann NY Acad Sci 2003 ; 996 : 26-38.
47. Radich JP, Dai H, Mao M, et al. Gene expression changes associatedwith progression and response in chronic myeloid leukemia. Proc NatlAcad Sci USA 2006 ; 103 : 2794-2799.
48. Nowicki MO, Pawlowski P, Fischer T, et al. Chronic myelogenousleukemia molecular signature. Oncogene 2003 ; 22 : 3952-3963.
49. Zheng C, Li L, Haak M, et al. Gene expression profi ling ofCD34 cells identifi es a molecular signature of chronic myeloidleukemia blast crisis. Leukemia 2006; 20: 1028-1034.
50. O ' Brien S G, Guilhot F, Larson R A, et al. Imatinib compared withinterferon and low-dose cytarabine for newly diagnosed chronic-phasechronic myeloid leukemia. NEngl J Med 2003; 348: 994-1004.
51. Deininger M, O ' Brien SG, Guilhot F, et al. International randomizedstudy of interferon vs STI571 (IRIS) 8-year follow up: sustained survivaland low risk for progression or events in patients with newly diagnosedchronic myeloid leukemia in chronic phase (CML-CP) treated withimatinib. Blood 2009; 114(Suppl. 1): Abstract 1126.
52. Druker B J, Guilhot F, O ' Brien S G, et al. Five-year follow-up ofpatients receiving imatinib for chronic myeloid leukemia. NEngl J Med2006 ; 355 : 2408-2417.
53. Hochhaus A, O ' Brien SG, Guilhot F, et al. Six-year follow-upof patients receiving imatinib for the fi rst-line treatment of chronicmyeloid leukemia. Leukemia 2009; 23: 1054-1061.
54. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerabilityadaptedimatinib 800 mg/d versus 400 mg/d versus 400 mg/d plusinterferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011 ; 29 : 1634-1642.
55. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versusimatinib for the treatment of patients with newly diagnosed chronicphase, Philadelphia chromosome-positive, chronic myeloid leukaemia:24-month minimum follow-up of the phase 3 randomised ENESTndtrial. Lancet Oncol 2011 ; 12 : 841-851.
56. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinibin patients with newly diagnosed Philadelphia chromosome-positivechronic myeloid leukemia in chronic phase: ENESTnd 3-year followup. Leukemia 2012; 26: 2197-2203.
57. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinibfor newly diagnosed chronic myeloid leukemia. NEngl J Med2010 ; 362 : 2251-2259.
58. Cortes JE, Jones D, O ' Brien S, et al. Nilotinib as front-linetreatment for patients with chronic myeloid leukemia in early chronicphase. J Clin Oncol 2010 ; 28 : 392-397.
59. Quintas-Cardama A, Kantarjian HM, Luthra R, et al. Effi cacyof frontline nilotinib therapy in patients (Pts) with newly diagnosedPhiladelphia chromosome (Ph)-positive chronic myeloid leukemia inearly chronic phase (CML-CP). Blood 2011; 118(Suppl. 1): Abstract 454.
60. Gugliotta G, Castagnetti F, Breccia M, et al. Early CP CML, nilotinib 400 mg twice daily frontline: beyond 3 years, results remainexcellent and stable (a GIMEMA CML Working Party Trial). Blood2011; 118(Suppl. 1): Abstract 2756.
61. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontlinetreatment of Ph chronic myeloid leukemia. Blood 2009 ; 114 :4933-4938.
62. O ' Dwyer EO, Swords R, Giles F, et al. Nilotinb 300 mg twice daily iseff ective and well tolerated as fi rst line treatment of Ph-positive chronicmyeloid leukemia in chronic phase: updated results of the ICORG 0802phase study. Haematologica 2010; 95(Suppl.): 340, Abstract 0812.
63. O ' Dwyer MC, Kent E, Parker M, et al. Nilotinib 300 mgtwice daily is effective and well tolerated as first line treatment ofPh-positive chronic myeloid leukemia in chronic phase: preliminaryresults of the ICORG 0802 phase 2 study. Blood 2009 ; 114(Suppl. 1) :Abstract 3294.
64. O ' Dwyer ME, Swords R, Giles F, et al. Analysis of the GeneXpertSystem on the international multicentre ICORG 08-02 phase II study ofnilotinib 300mg BID as frontline treatment in patients wiThearly chronicphase chronic myeloid leukemia (ECPCML). Blood 2011 ; 118(Suppl. 1) :Abstract 3774.
65. Hochhaus A, Shah NP, Cortes JE, et al. Dasatinib versus imatinib(IM) in newly diagnosed chronic myeloid leukemia in chronic phase(CML-CP): DASISION 3-year follow-up. J Clin Oncol 2012 ; 30(Suppl.) :Abstract 6504.
66. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versusimatinib in newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med 2010; 362: 2260-2270.
67. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinibin newly diagnosed chronic-phase chronic myeloid leukemia: 2-yearfollow-up from a randomized phase 3 trial (DASISION). Blood2012 ; 119 : 1123-1129.
68. Cortes JE, Jones D, O ' Brien S, et al. Results of dasatinib therapyin patients wiThearly chronic-phase chronic myeloid leukemia. J Clin Oncol 2010 ; 28 : 398-404.
69. Radich JP, Kopecky KJ, Appelbaum FR, et al. Arandomized trial ofdasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phasechronic myeloid leukemia. Blood 2012 ; 120 : 3898-3905.
70. Cortes J E, Kim D W, Kantarjian H M, et al. Bosutinib versusimatinib in newly diagnosed chronic-phase chronic myeloid leukemia:results from the BELA trial. J Clin Oncol 2012 ; 30 : 3486-3492.
71. Buchdunger E, Zimmermann J, Mett H, et al. Inhibitionof the Abl protein-tyrosine kinase in vitro and in vivo by a2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
72. Kantarjian HM, Kim D-W, Issaragrisil S, et al. Enestnd 4-year(y) update: continued superiority of nilotinib vs imatinib in patients(pts) with newly diagnosed Philadelphia chromosome-positive (Ph)chronic myeloid leukemia in chronic phase (CML-CP). Blood2012; 120(Suppl. 1): Abstract 1676.
73. Alvarado Y, Kantarjian H, O ' Brien S, et al. Signifi cance ofsuboptimal response to imatinib, as defi ned by the EuropeanLeukemiaNet, in the long-term outcome of patients wiThearly chronicmyeloid leukemia in chronic phase. Cancer 2009 ; 115 : 3709-3718.
74. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecularand cytogenetic response is predictive for long-term progression-freeand overall survival in chronic myeloid leukemia (CML). Leukemia2012 ; 26 : 2096-2102.
75. Hughes T P, Hochhaus A, Branford S, et al. Long-termprognostic signifi cance of early molecular response to imatinib innewly diagnosed chronic myeloid leukemia: an analysis from theInternational Randomized Study of Interferon and STI571 (IRIS). Blood2010 ; 116 : 3758-3765.
76. Jabbour E, Kantarjian H, O ' Brien S, et al. The achievementof an early complete cytogenetic response is a major determinantfor outcome in patients wiThearly chronic phase chronic myeloidleukemia treated with tyrosine kinase inhibitors. Blood 2011 ; 118 :4541-4546 ; quiz 4759.
77. Marin D, Ibrahim A R, Lucas C, et al. Assessment of BCR-ABL1transcript levels at 3 months is the only requirement for predictingoutcome for patients with chronic myeloid leukemia treated withtyrosine kinase inhibitors. J Clin Oncol 2012 ; 30 : 232-238.
78. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNetcriteria for failure or suboptimal response reliably identify patientswith CML in early chronic phase treated with imatinib whose eventualoutcome is poor. Blood 2008 ; 112 : 4437-4444.
79. Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayedachievement of cytogenetic and molecular response is associated withincreased risk of progression among patients with chronic myeloidleukemia in early chronic phase receiving high-dose or standard-doseimatinib therapy. Blood 2009; 113: 6315-6321.
80. Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve acomplete hematologic response at the time of a major cytogeneticresponse with second-generation tyrosine kinase inhibitors isassociated with a poor prognosis among patients with chronic myeloidleukemia in accelerated or blast phase. Blood 2009 ; 113 : 5058-5063.
81. Piazza RG, Magistroni V, Franceschino A, et al. The achievementof durable complete cytogenetic remission in late chronic andaccelerated phase patients with CML treated with imatinib mesylatepredicts for prolonged response at 6 years. Blood Cells Mol Dis2006 ; 37 : 111-115.
82. Hochhaus A, Guilhot F, Al-Ali KH, et al. Early BCR-ABL transcriptlevels predict future molecular response and long-term outcomes innewly diagnosed patients with chronic myeloid leukemia in chronicphase: analysis of ENESTnd 3-year data [Abstract 0584]. Presented atthe 17th Congress of the European Hematology Association, 14-17 June2012, Amsterdam, The Netherlands.
83. Hochhaus A, Boqué C, Bradley Garelik M, et al. Molecularresponse kinetics and BCR-ABL reductions in patients with newlydiagnosed chronic myeloid leukemia in chronic phase (CML-CP)receiving dasatinib vs imatinib: DASISION 3-year follow-up [Abstract0192]. Presented at the 17th Congress of the European HematologyAssociation, 14-17 June 2012, Amsterdam, The Netherlands.
84. Jabbour E, Cortes J, Santos FP, et al. Results of allogeneichematopoietic stem cell transplantation for chronic myelogenousleukemia patients who failed tyrosine kinase inhibitors afterdeveloping BCR-ABL1 kinase domain mutations. Blood 2011 ; 117 :3641-3647.
85. Quintas-Cardama A, Kantarjian H, O ' Brien S, et al. Outcome ofpatients with chronic myeloid leukemia with multiple ABL1 kinasedomain mutations receiving tyrosine kinase inhibitor therapy.Haematologica 2011; 96: 918-921.
86. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in latechronic phase chronic myeloid leukemia patients with up-frontcytogenetic resistance to imatinib are associated with a greaterlikelihood of progression to blast crisis and shorter survival: a studyby the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005 ; 23 : 4100-4109.
87. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABLmutations in patients with CML treated with imatinib is virtuallyalways accompanied by clinical resistance, and mutations in the ATPphosphate-binding loop (P-loop) are associated with a poor prognosis.Blood 2003 ; 102 : 276-283.
88. Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generationinhibitors of BCR-ABL for the treatment of imatinib-resistant chronicmyeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
89. Hochhaus A, Saglio G, Larson R A, et al. Nilotinib is associatedwith a reduced incidence of BCR-ABL mutations vs imatinib in patientswith newly diagnosed chronic myeloid leukemia in chronic phase.Blood 2013 ; 121 : 3703-3708.
90. Fabarius A, Leitner A, Hochhaus A, et al. Impact of additionalcytogenetic aberrations at diagnosis on prognosis of CML: long-termobservation of 1151 patients from the randomized CML Study IV. Blood2011 ; 118 : 6760-6768.
91. Verma D, Kantarjian H, Shan J, et al. Survival outcomes for clonalevolution in chronic myeloid leukemia patients on second generationtyrosine kinase inhibitor therapy. Cancer 2010; 116: 2673-2681.
92. Hasford J, Pfirrmann M, Hehlmann R, et al. Anew prognosticscore for survival of patients with chronic myeloid leukemia treatedwith interferon alfa. Writing Committee for the CollaborativeCML Prognostic Factors Project Group. JNatl Cancer Inst 1998 ; 90 :850-858.
93. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discriminationin " good-risk " chronic granulocytic leukemia. Blood 1984 ; 63 :789-799.
94. Oyekunle AA, Osho PO, Aneke JC, et al. The predictive value ofthe Sokal and Hasford scoring systems in chronic myeloid leukaemiain the imatinib era. JHematol Malign 2012; 2: 25-32.
95. Hasford J, Baccarani M, Hoffmann V, et al. Predicting completecytogenetic response and subsequent progression-free survival in 2060patients with CML on imatinib treatment: the EUTOS score. Blood2011 ; 118 : 686-692.
96. Hoffmann VS, Baccarani M, Lindoerfer D, et al. The EUTOSprognostic score: review and validation in 1288 patients with CMLtreated frontline with imatinib. Leukemia 2013 June 11. [Epub aheadof print]
97. Uz B, Buyukasik Y, Atay H, et al. EUTOS CML prognostic scoringsystem predicts ELN-based " event-free survival " better than Euro/Hasford and Sokal systems in CML patients receiving front-lineimatinib mesylate. Hematology 2013 ; 18 : 247-252.
98. Marin D, Ibrahim AR, Goldman JM. European Treatment andOutcome Study (EUTOS) score for chronic myeloid leukemia stillrequires more confi rmation. J Clin Oncol 2011 ; 29 : 3944-3945.
99. Sprycel (dasatinib) [prescribing information]. Princeton, NJ:Bristol-Myers Squibb Co.; 2011.
100. Gleevec (imatinib) [prescribing information]. East Hanover, NJ:Novartis Pharmaceuticals Corporation; 2012.
101. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ:Novartis Pharmaceuticals Corporation; 2012.
102. Bosulif (bosutinib) [prescribing information]. New York, NY:Pfi zer Laboratories ; 2012.
103. Cortes J E, Kantarjian H, Shah N P, et al. Ponatinib in refractoryPhiladelphia chromosome-positive leukemias. NEngl J Med2012 ; 367 : 2075-2088.
104. Radich JP. The biology of CML blast crisis. Hematology Am SocHematol Educ Program 2007: 384-391.
105. Kantarjian HM, O ' Brien S, Cortes JE, et al. Treatment ofPhiladelphia chromosome-positive, accelerated-phase chronicmyelogenous leukemia with imatinib mesylate. Clin Cancer Res2002 ; 8 : 2167-2176.
106. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durablehematologic and cytogenetic responses in patients with acceleratedphase chronic myeloid leukemia: results of a phase 2 study. Blood2002 ; 99 : 1928-1937.
107. Palandri F, Castagnetti F, Alimena G, et al. The long-termdurability of cytogenetic responses in patients with accelerated phasechronic myeloid leukemia treated with imatinib 600 mg: the GIMEMACML Working Party experience after a 7-year follow-up. Haematologica2009 ; 94 : 205-212.
108. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specifi cinhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronicmyeloid leukemia and acute lymphoblastic leukemia with thePhiladelphia chromosome. NEngl J Med 2001; 344: 1038-1042.
109. Kantarjian HM, Cortes J, O ' Brien S, et al. Imatinib mesylate(STI571) therapy for Philadelphia chromosome-positive chronicmyelogenous leukemia in blast phase. Blood 2002 ; 99 : 3547-3553.
110. Sawyers C L, Hochhaus A, Feldman E, et al. Imatinib induceshematologic and cytogenetic responses in patients with chronicmyelogenous leukemia in myeloid blast crisis: results of a phase IIstudy. Blood 2002 ; 99 : 3530-3539.
111. Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylateas treatment for blastic transformation of Philadelphia chromosomepositive chronic myelogenous leukemia. Haematologica 2003; 88: 1213-1220.
112. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloidleukemia in blast crisis treated with imatinib 600 mg: outcome ofthe patients alive after a 6-year follow-up. Haematologica 2008 ; 93 :1792-1796.
113. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerlyAMN107), ahighly selective BCR-ABL tyrosine kinase inhibitor, isactive in patients with imatinib-resistant or-intolerant acceleratedphasechronic myelogenous leukemia. Blood 2008 ; 111 : 1834-1839.
114. Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronicand accelerated phase chronic myeloid leukemia following failure ofimatinib and dasatinib therapy. Leukemia 2010; 24: 1299-1301.
115. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistantCML and Philadelphia chromosome-positive ALL. NEngl JMed 2006 ; 354 : 2542-2551.
116. Nicolini F E, Masszi T, Shen Z, et al. Expanding Nilotinib Accessin Clinical Trials (ENACT), an open-label multicenter study of oralnilotinib in adult patients with imatinib-resistant or-intolerant chronicmyeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma2012 ; 53 : 907-914.
117. Giles FJ, Kantarjian HM, le Coutre PD, et al. Nilotinib is eff ectivein imatinib-resistant or-intolerant patients with chronic myeloidleukemia in blastic phase. Leukemia 2012; 26: 959-962.
118. Guilhot F, Apperley J, Kim D W, et al. Dasatinib induces signifi canthematologic and cytogenetic responses in patients with imatinibresistantor- intolerant chronic myeloid leukemia in accelerated phase.Blood 2007 ; 109 : 4143-4150.
119. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatmentof chronic myeloid leukemia in accelerated phase after imatinib failure:the START A trial. J Clin Oncol 2009 ; 27 : 3472-3479.
120. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib140 mg once daily versus 70 mg twice daily in patients with chronicmyeloid leukemia in accelerated phase resistant or intolerant toimatinib: 15-month median follow-up. Blood 2009 ; 113 : 6322-6329.
121. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistantPhiladelphia chromosome-positive leukemias. NEngl J Med2006 ; 354 : 2531-2541.
122. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces completehematologic and cytogenetic responses in patients with imatinibresistantor-intolerant chronic myeloid leukemia in blast crisis. Blood2007 ; 109 : 3207-3213.
123. Cortes J, Kim DW, Raffoux E, et al. Effi cacy and safety of dasatinibin imatinib-resistant or-intolerant patients with chronic myeloidleukemia in blast phase. Leukemia 2008; 22: 2176-2183.
124. Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinibresistantor imatinib-intolerant chronic myeloid leukemia in blastphase after 2 years of follow-up in a phase 3 study: effi cacy andtolerability of 140 milligrams once daily and 70 milligrams twice daily.Cancer 2010 ; 116 : 3852-3861.
125. O ' Hare T, Shakespeare WC, Zhu X, et al. AP24534, apan-BCRABLinhibitor for chronic myeloid leukemia, potently inhibits theT315I mutant and overcomes mutation-based resistance. Cancer Cell2009 ; 16 : 401-412.
126. Cortes J E, Kim D W, Pinilla-Ibarz J, et al. PACE: a pivotal phaseII trial of ponatinib in patients with CML and PhALL resistant orintolerant to dasatinib or nilotinib, or with the T315I mutation. J Clin Oncol 2012; 30(Suppl.) Abstract:6503.
127. Eide CA, Adrian LT, Tyner JW, et al. The ABL switch controlinhibitor DCC-2036 is active against the chronic myeloid leukemiamutant BCR-ABLT315I and exhibits a narrow resistance profi le. CancerRes 2011; 71: 3189-3195.
128. Cortes JE, Talpaz M, Kantarjian HM, et al. Aphase 1 study ofDCC-2036, anovel oral inhibitor of BCR-ABL kinase, in patients withPhiladelphia chromosome positive (Ph) leukemias including patientswith T315I mutation. Blood 2011; 118(Suppl. 1): Abstract 601.
129. National Cancer Institute. SEER Stat Fact Sheets: ChronicMyeloid Leukemia. Available from: http://seer.cancer.gov/statfacts/html/cmyl.html
130. Saussele S, Lauseker M, Gratwohl A, et al. Allogeneichematopoietic stem cell transplantation (allo SCT) for chronicmyeloid leukemia in the imatinib era: evaluation of its impactwithin a subgroup of the randomized German CML Study IV. Blood2010 ; 115 : 1880-1885.
131. Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors foroutcomes in allogeneic transplantation for CML in the imatinib era: aCIBMTR analysis. Bone Marrow Transplant 2012 ; 47 : 810-816.
132. National Comprehensive Cancer Network. NCCN ClinicalPractice Guidelines in Oncology. Chronic myelogenous leukemia.Version 1.2013. Available from: http://www.nccn.org/professionals/physician-gls/pdf/cml.pdf
133. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: anupdate of concepts and management recommendations of EuropeanLeukemiaNet. J Clin Oncol 2009 ; 27 : 6041-6051.
134. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinasedomain mutation analysis in chronic myeloid leukemia patients treatedwith tyrosine kinase inhibitors: recommendations from an expert panelon behalf of European LeukemiaNet. Blood 2011 ; 118 : 1208-1215.
135. Laneuville P, Dilea C, Yin O Q, et al. Comparative in vitro cellulardata alone are insuffi cient to predict clinical responses and guide thechoice of BCR-ABL inhibitor for treating imatinib-resistant chronicmyeloid leukemia. J Clin Oncol 2010 ; 28 : e169-e171 ; author reply e172.
136. Cervantes F, Rozman M, Rosell J, et al. Astudy of prognosticfactors in blast crisis of Philadelphia chromosome-positive chronicmyelogenous leukaemia. Br J Haematol 1990; 76: 27-32.
137. Inverardi D, Lazzarino M, Morra E, et al. Extramedullary diseasein Ph '-positive chronic myelogenous leukemia: frequency, clinicalfeatures and prognostic signifi cance. Haematologica 1990; 75: 146-148.
138. Wadhwa J, Szydlo RM, Apperley JF, et al. Factors aff ectingduration of survival after onset of blastic transformation of chronicmyeloid leukemia. Blood 2002 ; 99 : 2304-2309.
139. Bornhauser M, Jenke A, Freiberg-Richter J, et al. CNS blast crisisof chronic myelogenous leukemia in a patient with a major cytogeneticresponse in bone marrow associated with low levels of imatinibmesylate and its N-desmethylated metabolite in cerebral spinal fl uid.Ann Hematol 2004 ; 83 : 401-402.
140. Leis J F, Stepan D E, Curtin P T, et al. Central nervous system failurein patients with chronic myelogenous leukemia lymphoid blast crisisand Philadelphia chromosome positive acute lymphoblastic leukemiatreated with imatinib (STI-571). Leuk Lymphoma 2004 ; 45 : 695-698.
141. Neville K, Parise RA, Thompson P, et al. Plasma and cerebrospinalfl uid pharmacokinetics of imatinib after administration to nonhumanprimates. Clin Cancer Res 2004 ; 10 : 2525-2529.
142. Petzer AL, Gunsilius E, Hayes M, et al. Low concentrationsof STI571 in the cerebrospinal fl uid: a case report. Br J Haematol2002 ; 117 : 623-625.
143. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRDmay predict the outcome of patients with Philadelphia chromosomepositiveALL treated with tyrosine kinase inhibitors plus chemotherapy.Blood 2013 ; 122 : 1214-1221.
144. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of lowdosedecitabine in combination with imatinib mesylate in patientswith accelerated or myeloid blastic phase of chronic myelogenousleukemia. Cancer 2007 ; 109 : 899-906.
145. Verma D, Kantarjian HM, Jones D, et al. Chronic myeloidleukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic signifi cance. Blood 2009; 114: 2232-2235.
146. Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined withmitoxantrone/etoposide and cytarabine is an eff ective inductiontherapy for patients with chronic myeloid leukemia in myeloid blastcrisis. Cancer 2007 ; 109 : 1543-1549.
147. Fang B, Li N, Song Y, et al. Standard-dose imatinib plus low-dosehomoharringtonine and granulocyte colony-stimulating factor is aneff ective induction therapy for patients with chronic myeloid leukemiain myeloid blast crisis who have failed prior single-agent therapy withimatinib. Ann Hematol 2010 ; 89 : 1099-1105.
148. Deau B, Nicolini FE, Guilhot J, et al. The addition of daunorubicinto imatinib mesylate in combination with cytarabine improves theresponse rate and the survival of patients with myeloid blast crisis chronicmyelogenous leukemia (AFR01 study). Leuk Res 2011; 35: 777-782.
149. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al.A pilot study of imatinib, low-dose cytarabine and idarubicin forpatients with chronic myeloid leukemia in myeloid blast phase. LeukLymphoma 2007; 48: 283-289.